In summary, the highly consistent results across multiple experimental systems reinforced our conclusion that the CRISPR/Cas13d system showed robust efficiency for selectively targeting GGGGCC repeat RNAs in C9-ALS patient cells and that the knockdown of RAN translation products was achieved through a combination of RNA cleavage and translational repression mechanisms. The gene discussed is C9; the disease is amyotrophic lateral sclerosis.